# Beam Therapeutics Reports Positive Topline Data From Sickle Cell Trial

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/54255
Published: 2026-11-11T17:19:02.000Z
Updated: 2026-11-11T17:19:02.000Z
Section: Business

> The Phase 1/2 BEACON study met its primary efficacy endpoint and all primary safety endpoints at an interim analysis.

Beam Therapeutics announced positive topline results from its BEACON Phase 1/2 trial of ristoglogene autogetemcel (risto-cel), a cell therapy for sickle cell disease.

At an interim analysis, the study met its primary efficacy endpoint and all primary safety endpoints. Beam characterized the findings as positive topline data.